Young NS. Acquired aplastic anemia. Ann Intern Med.2002;136:534-546.
Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med.1997;336:1365-1372.
Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired
aplastic anemia. Semin Hematol.2000;37:30-42.
Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without
allogeneic bone-marrow infusions. Lancet.1977;2:1145-1148.
Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated
bone marrow failure syndromes. Int J Hematol.2002;75:129-140.
Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red
cell aplasia. Br J Haematol.1989;72:278-284.
Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W. Oral cyclosporin-A is effective treatment for untreated and also for
previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol.1989;43:136-142.
Frickhofen N, Kaltwasser JP, Schrezenmeier H.
et al. for the German Aplastic Anemia Study Group. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone
with or without cyclosporine. N Engl J Med.1991;324:1297-1304.
Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine
as treatment for severe acquired aplastic anemia. Blood.1995;85:3058-3065.
Bacigalupo A, Broccia G, Corda G.
et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating
factor in patients with acquired severe aplastic anemia (SAA): a pilot study
of the EBMT SAA working party. Blood.1995;85:1348-1353.
Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol.2000;37:91-101.
Moore MA, Castro-Malaspina H. Immunosuppression in aplastic anemia: postponing the inevitable? N Engl J Med.1991;324:1358-1360.
Brodsky RA, Sensenbrenner LL, Smith BD.
et al. Durable treatment-free remission after high dose cyclophosphamide therapy
for previously severe aplastic anemia. Ann Intern Med.2001;135:477-483.
Margolis D, Camitta B, Pietryga D, Keever-Taylor C. Unrelated donor bone marrow transplantation to treat severe aplastic
anaemia in children and young adults. Br J Haematol.1996;94:65-72.
Deeg HJ, Seidel K, Casper J.
et al. Marrow transplantation from unrelated donors for patients with severe
aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant.1999;5:243-252.
Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
Gooley TA, Leisenring W, Crowley JP, Storer BE. Estimation of failure probabalities in the prescence of competing risks:
new respresentations of old estimators. Stat Med.1999;18:695-706.
Williams DM, Lynch RE, Cartwright GE. Prognostic factors in aplastic anaemia. Clin Haematol.1978;7:467-474.
Camitta BM, Thomas D, Nathan DG.
et al. A prospective study of androgens and bone marrow transplantation for
treatment of severe aplastic anemia. Blood.1979;53:504-514.
Bacigalupo A, Brand R, Oneto R.
et al. for the European Group for Blood and Marrow Transplantation experience. Treatment of acquired severe aplastic anemia: bone marrow transplantation
compared with immunosuppressive therapy. Semin Hematol.2000;37:69-80.
Kojima S, Hibi S, Kosaka Y.
et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine,
and danazol with or without human granulocyte colony-stimulating factor in
children with acquired aplastic anemia. Blood.2000;96:2049-2054.
Tichelli A, Socié G, Henry-Amar M.
et al. for the European Group for Blood and Marrow Transplantation Several
Aplastic Anaemia Working Party. Effectiveness of immunosuppressive therapy in older patients with aplastic
anemia. Ann Intern Med.1999;130:193-201.
Bacigalupo A, Bruno B, Saracco P.
et al. for the European Group for Blood and Marrow Transplantation (EBMT)
Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti
di Midolio Osseo (GITMO). Antilymphocyte globuilin, cyclosporine, prednisolone, and granulocyte
colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT
study on 100 patients. Blood.2000;95:1931-1934.
Schrezenmeier H, Marin P, Raghavachar A.
et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report
from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol.1993;85:371-377.
Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T-cell receptor VB usage in aplastic anemia. J Clin Invest.2001;108:765-773.
Kook H, Risitano A, Zeng W.
et al. Changes in T-cell receptor Vb-repertoire in aplastic anemia: effects
of different immunosuppressive regimens. Blood.2002 May 15;99(10):3668-3675.
Tichelli A, Gratwohl A, Nissen C, Speck B. Late clonal complications in severe aplastic anemia. Leuk Lymphoma.1994;12:167-175.
Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence
of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol.2001;115:1015-1022.
Barrett AJ, Saunthararajah Y. Myelodysplastic syndrome and aplastic anemia—distinct entities
or dieases linked by a common pathophysiology? Semin Hematol.2000;37:15-29.
Maciejewski JP, Risitano AM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from
aplastic anemia. Blood.2002;99:3129-3135.
Di Bona E, Rodeghiero F, Bruno B.
et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte
colony stimulating factor is an effective treatment for aplastic anaemia patients
unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol.1999;107:330-334.
Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe
aplastic anemia. Semin Hematol.2000;37:43-55.